Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Additional medications, known as the pillars of heart ... someone with a new diagnosis of heart failure may start on a low dose of ARNI and beta-blocker, and within a few days or weeks, add ...

The SARAH clinical trial examined the effects of the heart-failure medication sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor or ARNI, on preventing further heart damage among ...

BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...